Sagittarius Life Science (ROCO:3205) Cyclically Adjusted Revenue per Share: NT$18.89 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:3205 Sagittarius Life Science Corp ROCO:3205
46 GF Score
Price NT$47.60
GF Value NT$19.70
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Sagittarius Life Science Cyclically Adjusted Revenue per Share?

Sagittarius Life Science ROCO:3205 -0.31% 46 Cyclically Adjusted Revenue per Share is NT$18.89 as of Mar. 2026. GuruFocus rates ROCO:3205 with a GF Score™ of 46/100 and a GF Value™ of NT$19.70 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sagittarius Life Science's adjusted revenue per share for the three months ended in Mar. 2026 was NT$2.217. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$18.89 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Sagittarius Life Science's average Cyclically Adjusted Revenue Growth Rate was -24.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -5.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sagittarius Life Science was 5.80% per year. The lowest was -5.20% per year. And the median was 3.90% per year.

As of today (2026-08-01), Sagittarius Life Science's current stock price is NT$47.60. Sagittarius Life Science's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$18.89. Sagittarius Life Science's Cyclically Adjusted PS Ratio of today is 2.52.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sagittarius Life Science was 3.29. The lowest was 0.87. And the median was 1.72.


Sagittarius Life Science  (ROCO:3205) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sagittarius Life Science's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=47.60/18.89
=2.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sagittarius Life Science was 3.29. The lowest was 0.87. And the median was 1.72.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sagittarius Life Science Cyclically Adjusted Revenue per Share Related Terms


Sagittarius Life Science Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Sagittarius Life Science's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagittarius Life Science Cyclically Adjusted Revenue per Share Chart

Sagittarius Life Science Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.27 24.55 25.27 25.24 20.92

Sagittarius Life Science Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.01 24.38 23.12 20.92 18.89

ROCO:3205 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Sagittarius Life Science's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sagittarius Life Science Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagittarius Life Science's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sagittarius Life Science's Cyclically Adjusted PS Ratio falls into.


ROCO:3205
46GF Score
Sagittarius Life Science Corp ROCO:3205
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagittarius Life Science Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sagittarius Life Science's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.217/330.2130*330.2130
=2.217

Current CPI (Mar. 2026) = 330.2130.

Sagittarius Life Science Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 15.448 241.018 21.165
201609 6.412 241.428 8.770
201612 4.986 241.432 6.819
201703 4.148 243.801 5.618
201706 3.553 244.955 4.790
201709 3.460 246.819 4.629
201712 3.013 246.524 4.036
201803 3.292 249.554 4.356
201806 3.171 251.989 4.155
201809 2.889 252.439 3.779
201812 2.986 251.233 3.925
201903 2.925 254.202 3.800
201906 3.674 256.143 4.736
201909 3.482 256.759 4.478
201912 3.285 256.974 4.221
202003 4.542 258.115 5.811
202006 4.129 257.797 5.289
202009 3.953 260.280 5.015
202012 4.460 260.474 5.654
202103 4.531 264.877 5.649
202106 4.695 271.696 5.706
202109 4.461 274.310 5.370
202112 4.316 278.802 5.112
202203 4.128 287.504 4.741
202206 4.117 296.311 4.588
202209 4.128 296.808 4.593
202212 3.815 296.797 4.245
202303 3.520 301.836 3.851
202306 3.491 305.109 3.778
202309 3.288 307.789 3.528
202312 3.242 306.746 3.490
202403 3.596 312.332 3.802
202406 3.613 314.175 3.797
202409 3.509 315.301 3.675
202412 3.623 315.605 3.791
202503 1.494 319.799 1.543
202506 2.363 322.561 2.419
202509 1.372 324.800 1.395
202512 0.587 324.054 0.598
202603 2.217 330.213 2.217

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$18.89 mean?
Sagittarius Life Science (ROCO:3205) has a Cyclically Adjusted Revenue per Share of NT$18.89 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sagittarius Life Science and its competitors.
Is Sagittarius Life Science's Cyclically Adjusted Revenue per Share too high?
Sagittarius Life Science's current Cyclically Adjusted Revenue per Share is NT$18.89. Overall, Sagittarius Life Science has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sagittarius Life Science's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Sagittarius Life Science's Cyclically Adjusted Revenue per Share of NT$18.89 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sagittarius Life Science and its competitors. Sagittarius Life Science's current Cyclically Adjusted Revenue per Share is NT$18.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagittarius Life Science stock overvalued right now?
Based on GuruFocus' analysis, Sagittarius Life Science (ROCO:3205) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$19.70, compared to a current price of NT$47.60 — trading 141.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$18.89. Sagittarius Life Science's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Sagittarius Life Science (ROCO:3205), the current Cyclically Adjusted Revenue per Share is NT$18.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sagittarius Life Science (ROCO:3205) Overvalued in 2026?

Based on GuruFocus' analysis, Sagittarius Life Science stock appears to be overvalued. The current stock price of NT$47.60 is trading 141.6% above its estimated GF Value™ of NT$19.70. GuruFocus considers Sagittarius Life Science to be Significantly Overvalued.

Key valuation signals for ROCO:3205:

  • Cyclically Adjusted Revenue per Share: NT$18.89
  • GF Value™: NT$19.70 vs. price of NT$47.60 (141.6% above fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the ROCO:3205 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sagittarius Life Science Business Description

Address No. 3, Park Street, 10-6th Floor, Nangang District, Taipei, TWN
Sagittarius Life Science Corp is a Taiwan-based company engaged in the biotechnology and pharmaceutical sectors. The segment includes: Food and Others, with the majority of revenue from Food.
46GF Score

Get the complete analysis for ROCO:3205

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$47.60
Price
NT$19.70
GF Value